Increased Free (Unconjugated) Bile Acids in Disease States

1. Hypercholesterolemia

• Bile acids are the major pathway for cholesterol catabolism - the liver converts cholesterol to primary bile acids (cholic acid, chenodeoxycholic acid) via CYP7A1.
• In hypercholesterolemia, the liver is exposed to excess cholesterol, which drives upregulation of bile acid synthesis to compensate. This increases the total bile acid pool.
• Additionally, bile acid sequestrants (cholestyramine, colestipol, colesevelam) are used as treatment - they bind bile acids in the gut, interrupting enterohepatic recirculation, leading to increased fecal loss of bile acids and forcing the liver to synthesize more from cholesterol, reducing serum LDL.
• The result: increased circulating and luminal free bile acids, with compensatory upregulation of hepatic LDL receptors.
• Patients with hyperlipoproteinemia treated with cholestyramine showed increased bile acid and triglyceride levels as a consequence of this feedback - Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease (PMC8330388).

In short: excess cholesterol substrate → increased CYP7A1-driven bile acid synthesis → larger bile acid pool → more free bile acids.

2. Hyperlipidemia

• In conditions like NAFLD/NASH (a common sequel to hyperlipidemia), serum and urine bile acid concentrations are significantly elevated compared to healthy subjects. Plasma glycine cholate, taurocholate, and glycine deoxycholate are all raised.
• Bile acid homeostasis is dysregulated through:
  • Disrupted FXR (Farnesoid X Receptor) signaling - impaired FXR-SHP-CYP7A1 feedback axis fails to suppress bile acid synthesis
  • Increased basolateral efflux of bile acids from hepatocytes (via MRP3, MRP4, OSTα-OSTβ) into systemic circulation
  • Gut dysbiosis - increased bacterial deconjugation of bile acids, producing more free (unconjugated) secondary bile acids (deoxycholic acid, lithocholic acid) that passively diffuse into circulation
• The levels of free bile acids correlate with severity of portal inflammation, lobular inflammation, steatosis, and hepatocyte ballooning - Sleisenger & Fordtran's GI and Liver Disease.

3. Chronic Liver Disease (CLD)

1. Hepatic blood flow
2. Hepatic uptake (via NTCP/SLC10A1 transporter)
3. Bile acid secretion into canaliculi
4. Intestinal transit

• Impaired hepatic first-pass extraction - damaged hepatocytes downregulate NTCP, so bile acids escaping intestinal reabsorption are not cleared from portal blood and spill into systemic circulation.
• Cholestasis - impaired canalicular secretion (BSEP/ABCB11 dysfunction) causes bile acid backflow into sinusoidal blood.
• Portosystemic shunting - blood bypasses hepatocytes entirely, carrying bile acids directly into systemic circulation.
• Adaptive response to bile acid overload - hepatocytes upregulate basolateral efflux transporters (MRP3, MRP4, OSTα-OSTβ) to export bile acids into the space of Disse → systemic blood → kidney → urine.
• The unconjugated fraction rises because conjugation capacity is also impaired in severe liver dysfunction.

• In cirrhosis specifically: all four mechanisms operate simultaneously, producing markedly elevated serum free bile acids. Elevated fasting serum bile acids serve as early markers of intrahepatic cholestasis of pregnancy (ICP) by the same mechanism.

4. Chronic Kidney Disease (CKD)

• Normally, 10-50% of bile acids returning in portal blood escape hepatic extraction and spill into systemic circulation. These are filtered at the glomerulus (the unbound fraction) and reabsorbed in the proximal tubule via ASBT (apical sodium bile acid transporter, SLC10A2) and exported via basolateral OSTα-OSTβ.
• Binding to plasma proteins reduces glomerular filtration and normally limits urinary bile acid excretion.

1. Reduced GFR - fewer bile acids are filtered and excreted renally, causing systemic accumulation.
2. Tubular transporter dysfunction - ASBT activity is impaired in CKD, and reabsorbed bile acids cannot be efficiently returned to the portal circulation.
3. Gut dysbiosis in CKD - altered microbiome increases deconjugation of primary bile acids, generating more unconjugated (free) secondary bile acids (deoxycholic acid, lithocholic acid) that are passively absorbed.
4. Concurrent hyperlipidemia - CKD patients commonly have dyslipidemia (>90% of CKD patients have total cholesterol >240 mg/dL), driving increased bile acid synthesis.
5. Uremic milieu - uremic toxins impair hepatic bile acid uptake transporters, compounding systemic accumulation.

Summary Table

• NTCP (SLC10A1): hepatic bile acid uptake - impaired in CLD
• BSEP (ABCB11): canalicular secretion - impaired in cholestasis/CLD
• ASBT (SLC10A2): ileal and renal tubular reabsorption - impaired in CKD
• OSTα-OSTβ: basolateral efflux in liver, gut, and kidney - upregulated as adaptive response in bile acid overload
• MRP3/MRP4 (ABCC3/ABCC4): hepatic sinusoidal efflux - upregulated in CLD as hepatoprotective response